asa glp 1 Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists The anti-inflammatory feature of glucagon-like

Sequencing and Combination Use of SGLT2is and GLP-1 RAs There was agreement that sequential or upfront combination therapy with SGLT2is and GLP-1 RAs is appropriate for individuals with ongoing kidney progression, high cardiovascular risk or suboptimal metabolic control

Patients should be counseled that side effects are generally dose-dependent and transient

Common sources include: Soft drinks and soda Sweetened fruit juices and fruit drinks Energy and sports drinks Sweetened iced teas Flavoured coffee drinks and frapps Milkshakes Healthier swap: Water, sparkling water, unsweetened tea, black coffee, or naturally infused water

MEDVi was served on May 20, 2025

[DOI] [PubMed] [Google Scholar] Orskov C

The doses used in animal studies were also significantly higher than therapeutic doses used in clinical practice